2018-2022: New European COST Action Accepted
The QoL team contributes to the accepted European COST Action titled "CardioRNA: Catalysing Transcriptomics Research in Cardiovascular Disease".
European COST Action "CardioRNA: Catalysing Transcriptomics Research in Cardiovascular Disease"
The COST Action proposed by Cardiolinc Board Members Yvan Devaux and Clarissa Pedrosa da C. Gomes and co-proposed by other 19 Cardiolinc members and partners has been approved. The COST governing board announced on April 13th that this year it funded 39 out of the 422 eligible proposals. The new Actions will start in the second semester of 2018.
COST (Cooperation in Science and Technology) is longest-running European framework supporting international cooperation among researchers, engineers and scholars. COST Actions are networks with a duration of 4 years and participation of at least 5 COST Countries that receive support for networking activities and training.
The COST Action, titled CardioRNA - “Catalyzing transcriptomics research in cardiovascular disease”, aims to accelerate the understanding of transcriptomics in cardiovascular disease and further the translation of experimental data into practical applications for diagnostics and therapies to improve personalized medicine.
The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. CardioRNA aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic.
CardioRNA’s network of proposers is comprised of 21 proposers from 13 COST Countries and 1 International Partner Country. The participants comprise a group of experienced scientists and clinicians with complementary backgrounds in Molecular Biology, Biotechnology, Cardiology, Translational research, Computer Science, Bioinformatics, Clinical Research, Epigenetics, Biobanking, Biospecimen Science, Molecular Genetics and Pharmacology.
The QoL Team contributes to the ACtion with its digital health and Quality of Life Technologies expertise.
April 20, 2018